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Autoimmune hepatitis (AIH) is a relapsing inflammatory disease of the liver of unknown cause. It is characterized by the presence of hypergammaglobulinemia, serum autoantibodies, and liver infiltration with lymphocytes and plasma cells (1) . Unfortunately, little is known about the epidemiology, clinical course, and outcome of autoimmune hepatitis in Saudi Arabia.
In this study, we review all the patients diagnosed with autoimmune hepatitis in our gastroenterology unit at King Khalid university hospital in Riyadh.
Our aim is to (1) identify any special clinical or histological features in our patients that are different compared to the international literature (2) , describe the initial response to immunosuppressive therapy and long term relapse (3),identify clinical and laboratory predictors of response to therapy, and (4) examine the utility of laboratory markers (platelet count, AST/ALT ratio, and the AST to platelet ratio index (APRI score) in predicting the presence of advanced fibrosis defined as a fibrosis score of 3 or 4.
Methods
From a database of all liver biopsies performed in our unit from 1996-2004 we identified the biopsies with the final diagnosis of AIH. We then reviewed all the files and verified the pathological diagnosis with the clinical diagnosis and included in this study only patients with the pathological and clinical diagnosis of AIH. History and physical examination findings were collected from the patients' charts. Laboratory tests were obtained from the hospital computer database. Liver biopsy reports were obtained and reviewed for histological features of AIH.
We then reviewed the initial treatment given to the patient and evaluated the initial response to therapy. Initial response was defined as the clinical and biochemical data three months after starting therapy. Complete response was defined as normalization of the ALT and GGT after three months of therapy. Partial response was defined as 50% or more reduction in ALT or GGT values from pretreatment values. No response was defined as less that 50% reduction or any increase in the ALT or GGT values. These definitions are in keeping with the American Association for the study of the liver guidelines on the diagnosis and management of AIH (1) . We then recorded the maintenance therapy that the patients received and the outcome of this maintenance therapy. In this regard, a sustained remission was defined as totally normal liver enzymes and liver function tests 6 months after starting maintenance therapy.
We then compared between the patients who responded to therapy and patients who did not in terms of all the laboratory and histology parameters in an attempt to identify laboratory or histological predictors of response to therapy. Subsequently, we looked at the sensitivities, specificities, positive and negative predictive values, and receiver operator characteristic (ROC) curves to evaluate the accuracy of three 277 U/L. A negative anti-nuclear antibody (ANA) was seen well known laboratory parameters (platelet count, AST/ALT in 35% of patients, 18% had ANA between 1:20 and 1:120, ratio, and APRI score) in predicting the presence of advanced fibrosis defined as a fibrosis score of 3 or 4 on the METAVIR liver histology classification system (2) . In this particular analysis, we used the data from forty patients as there were data available on one more patient.
For all statistical analyses performed, the data was entered in MS Excel software. SPSS PC+ statistical software was used for the statistical analyses. The association between the categorical variables was assessed by using the Chi-square test or Fisher exact test. The sensitivity, specificity, and positive and negative predictive values were calculated to assess the variables (platelet count, AST/ALT ratio, and the APRI score) in prediction of the presence /absence of advanced fibrosis and cirrhosis.
Results
Of a database containing five hundred and twenty liver biopsies, fifty-seven patients were found to have AIH as the final diagnosis from their liver biopsy reports. After reviewing the patient's files, forty-eight patients were found to have both histological and clinical diagnosis of AIH. Of these fortyeight patients, nine patients were either lost to follow up after the liver biopsy or were found to have incomplete data, and so they were excluded. The remaining thirty-nine patients were included in this analysis. The mean age was 45.4 with the oldest patient being eighty years old and the youngest eighteen . Females constituted 65% of the patients.
Initial presentation
Ten patients presented with abnormal liver enzymes that were incidentally found to be raised but without any symptoms, eight patients presented with elevated liver enzymes and nonspecific symptoms, eighteen patients presented with jaundice, and three patients presented with severe acute hepatitis. Twenty-three patients had an associated autoimmune disease (the most common of which was thyroid disease).
Initial laboratory data are summarized in tabular form (table1). Mean ALT at presentation was 268 U/L and AST was and 47% had an ANA which was higher than 1:120. Antismooth muscle antibody (ASMA) was positive in 75%, 45% had ASMA between 1:20 and 1:120, and 30% had an ASMA higher than 1:120. Both ANA and ASMA were negative in 17% of the patients, 13% had both positive above 1:120, while all the remaining patients had either ANA or ASMA positive. Important histological data is also summarized in tabular form (table2).
Initial treatment and response
Of the thirty-nine patients who were treated in our center, twenty received prednisone 60 mg as their initial therapy while nineteen patients received a combination of prednisone 30 mg and azathioprine 50 mg. In both regimens, steroids were tapered quickly over a month. Eighteen patients (46%) had complete response, twelve (30%) had partial response, and nine (23%) had no response.
Maintenance therapy and follow up Patients were followed for an average duration of forty-five months. In regards to maintenance therapy, three patients (7.6%) were maintained on low dose prednisone therapy alone, eight (20.5%) were maintained on azathioproine and prednisone, while nineteen (48.7%) were maintained on azathioprine alone. One patient with sever acute hepatitis died and one refused to take maintenance therapy, while seven patients (18%) did not require maintenance therapy because they were totally asymptomatic and had normal liver enzymes after treatment. Within the duration of follow up, eight patients (20%) had at least one flare on maintenance therapy requiring reintroduction or increased dosage of prednisone. Two patients, who continued to have elevated liver enzymes on 30 mg of prednisone and 150 mg of azathioprime, were switched to mycophenolate mofetil (starting dose of 500 mg twice daily up to 1 gm twice daily) with subsequent normalization of their liver enzymes and without any serious side effects. Those two patients were successfully tapered from steroids completely. The remainder of the patients achieved sustained remission on maintenance therapy. Differences between initial responders and nonresponders We compared patients who had a complete or partial response to initial therapy with those who had no response (tables 1 and 2). We found that only the level of GGT was statistically significantly different between the two groups (173 vs. 499, p=0.002). GGT was also the only significantly different parameter found when the analysis was done with patients achieving complete response was compared to patients with partial response and no response combined.
Patients with advanced fibrosis at presentation
Fifteen patients (38%) had advanced fibrosis at presentation.
When these patients were compared to patients presenting without advanced fibrosis, no statistically significant differences were found except for the albumin level. Similarly, there were no significant differences between patients with advanced fibrosis and those without in terms of initial response to therapy or need for maintenance therapy.
Validation of fibrosis markers
The results for different parameters predicting fibrosis have been tabulated (table 3) . It was found that a platelet count above 100 had a sensitivity of 100% in predicting absence of advanced fibrosis but with a specificity of about 10%. AST/ ALT ratio more than 0.70 was also found to be predictive of advanced fibrosis with a sensitivity of 100%, but with a poor specificity of 50%. The APRI score was less sensitive and specific.
Similarly, using the ROC curves to compare between these predictive models, we found that both platelet count and AST/ ALT ratio gave reasonable area under the curve of 0.783 and 0.793 respectively, while the APRI score gave an area under the curve of 0.690.
Discussion
Our study of all patients with autoimmune hepatitis in our center showed that the clinical features of AIH at presentation, specifically age, sex distribution, associated diseases, liver enzymes elevations, and auto-antibodies are similar to what is described in the international literature (1;3) . Similarly, the percentage of patients with advanced fibrosis and cirrhosis (about 35%), the initial response to steroid therapy (around 80%), and the need for long term maintenance therapy (around 20%) were all compatible with the international literature. It has been noticed in many studies that racial, regional, and genetic factors may affect the presentation and outcome of patients with AIH. For example, cirrhosis is present more commonly in black North American patients with AIH than in white (4) . In addition, Blacks tend to be younger at presentation than their counterparts. Other studies in Alaskan natives, Turks, Japanese, South Americans, and non-European, nonwhite patients with AIH have shown marked differences in prevalence and prognosis (5) . Similar to the study by Roberts et al, we found that patients with cirrhosis had a similar response to therapy and a similar outcome compared to patients without cirrhosis (6) . These findings are in contrast to the recently published data from Canada showing a less favorable outcome of patients presenting with cirrhosis (7) . Two of our patients who did not respond to the combination of high dose steroid and azathioprine therapy were started on Mycophenolate mofetil with total response to therapy with no side effects. There has been increasing reports on the use of this agent in treating steroid resistant and steroid dependant patients (8;9) . When we looked at predictors of response to therapy we found that the level of GGT may be a useful laboratory based non-invasive predictor of response to therapy as it was the only laboratory parameter difference between responders and nonresponders, a finding not reported before to our knowledge. We found no histological parameters that may predict response to therapy. Liver biopsy has been shown to be useful prior to termination of treatment as interface hepatitis is found in 55% of patients with normal serum aminotransferases during therapy and these patients were shown to invariably relapse after cessation of treatment. 10 On the other hand, there is hardly any evidence in the literature regarding laboratory or histologic predictors of response to initial therapy.
This study is one of the first studies to validate the utility of platelet count, AST/ALT ratio, and APRI score in predicting advanced fibrosis in patients with AIH. These markers have been validated and found to be fairly sensitive and specific in hepatitis C mainly in international studies (11;12) . Our group has also validated the utility of these tests in local Saudi patients with hepatitis B and C (13) . In the present study, we found that the best utility of these markers in patients with autoimmune hepatitis is when a platelet count above 100 is used to predict the absence of advanced fibrosis and ASL/ALT ratio of more than 0.7 is used to predict the presence of advanced fibrosis (table 3) . The APRI score was less useful in this study in patients with AIH while being more useful in our previous study on local hepatitis B and C patients. These noninvasive markers should prove very useful in assessment and followup of patients with AIH.
Our study suffers from the usual shortcomings of retrospective analyses. In addition, the number of patients is too small to be able to offer concrete conclusions. Nevertheless, this study offers very useful information (some of which is original) regarding the management of patients with AIH.
In conclusion, by reviewing all the patients with AIH in our center we found that there are no peculiar features in our patients in terms of epidemiological factors, clinical presentation, laboratory parameters, and response to immunosuppressive therapy. We also found that the GGT level at presentation may serve as a useful predictor of response to therapy. Platelet count and AST/ALT ratio may be used to predict advanced fibrosis.
